Gilead’s remdesivir endorsed as first treatment for Covid-19 in Europe

EMA committee recommends drug’s use in adults and adolescents from 12 years of age

The European healthcare regulator has recommended the conditional approval of Gilead Sciences Inc's antiviral treatment, remdesivir, for use in Covid-19 patients, making it the first treatment to be on track to be green-lit in the continent.

The European Medicines Agency (EMA) said on Thursday its human medicines committee (CHMP) recommended the drug's use in adults and adolescents from 12 years of age with pneumonia who require oxygen support.

The price of the drug in the region is not yet known. In the United States, it could be priced up to $5,080 (€4,532) per course, while Indian generic drugmakers will sell the treatment between 5,000 rupees to 6,000 rupees.

The EMA endorsement, which comes just weeks after a speedy review, means physicians can prescribe the Gilead drug, to be branded Veklury, in Europe once approved by the European Commission, which usually follows CHMP recommendations.


The EU’s conditional marketing authorisation allows a treatment to be sold for a year in the 27-nation trading bloc before all necessary data on its efficacy and side-effects are available. Gilead has to submit final data by December.

Demand for the drug soared after it became a front-runner following promise in trials. Gilead expects supply of remdesivir to exceed two million courses by year-end, double its previous target, and is planning to begin testing of an easier-to-use inhaled version of the drug, given intravenously as of now.

Remdesivir has already been approved for emergency use in severely-ill patients in the United States, India and South Korea, and has received full approval in Japan. – Reuters